Dimensional Fund Advisors LP Acquires 9,017 Shares of iRadimed Corporation $IRMD

Dimensional Fund Advisors LP raised its holdings in iRadimed Corporation (NASDAQ:IRMD) by 4.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 226,146 shares of the medical equipment provider’s stock after purchasing an additional 9,017 shares during the period. Dimensional Fund Advisors LP’s holdings in iRadimed were worth $21,768,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. CWM LLC lifted its stake in shares of iRadimed by 19.5% during the 4th quarter. CWM LLC now owns 657 shares of the medical equipment provider’s stock valued at $64,000 after buying an additional 107 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of iRadimed by 5.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider’s stock worth $252,000 after acquiring an additional 234 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of iRadimed by 4.8% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,824 shares of the medical equipment provider’s stock worth $567,000 after acquiring an additional 267 shares during the period. Farther Finance Advisors LLC grew its position in shares of iRadimed by 827.1% in the fourth quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 397 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in shares of iRadimed by 10.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,782 shares of the medical equipment provider’s stock valued at $466,000 after purchasing an additional 458 shares in the last quarter. Institutional investors own 92.34% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut iRadimed from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, iRadimed currently has a consensus rating of “Moderate Buy” and a consensus price target of $120.00.

Insider Activity at iRadimed

In other news, CEO Roger E. Susi sold 5,000 shares of the business’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $87.51, for a total transaction of $437,550.00. Following the completion of the transaction, the chief executive officer owned 2,175,000 shares of the company’s stock, valued at approximately $190,334,250. The trade was a 0.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 17,500 shares of company stock worth $1,515,065 over the last ninety days. 34.60% of the stock is currently owned by insiders.

iRadimed Price Performance

Shares of NASDAQ:IRMD opened at $91.21 on Friday. The firm has a fifty day moving average price of $94.51 and a two-hundred day moving average price of $95.42. The company has a market cap of $1.17 billion, a price-to-earnings ratio of 50.96 and a beta of 0.90. iRadimed Corporation has a one year low of $67.51 and a one year high of $107.90.

iRadimed (NASDAQ:IRMD) last issued its quarterly earnings data on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.02. The company had revenue of $20.47 million for the quarter, compared to the consensus estimate of $20.35 million. iRadimed had a return on equity of 23.45% and a net margin of 26.70%.iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. Equities research analysts expect that iRadimed Corporation will post 1.52 EPS for the current fiscal year.

iRadimed Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 28th. Stockholders of record on Friday, August 14th will be given a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Friday, August 14th. iRadimed’s dividend payout ratio (DPR) is 44.69%.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.